This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's Mad Dash: Regeneron to $400; Conn's a No-Touch

NEW YORK (TheStreet) -- On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, was very excited about Regeneron's (REGN - Get Report) new cholesterol drug, Alirocumab. 

The company's anti-cholesterol drug is an alternative to statin and reduces the risk of strokes. Regeneron is partnered with Sanofi (SNY - Get Report) for Alirocumab. 

Read More: Dollar General Offers Major Antitrust Concessions as It Lifts Bid for Family Dollar

The stock is breaking out, Cramer said, adding that Credit Suisse suggests it can go to $400 per share. 

"It's a very big win for Regeneron. It could be a multi-billion market," he said. 

Turning to Conn's (CONN - Get Report) , Cramer noted that the stock is plummeting -- down over 30%. Management expressed concern that customers would not be paying Conn's the money it is owed. 

Investors want exposure to domestic retailers to protect themselves from geopolitical risks, Cramer said, but not all domestic retailers are created equal. 

He concluded that he is not a buyer of Conn's following the selloff, because a lot of investors still want to get out of the stock. 

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

Read More: 10 Most Affordable Cars Of 2014

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CONN $30.85 0.00%
REGN $480.09 0.00%
SNY $51.75 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs